Prescribing and facilitating withdrawal from benzodiazepines in primary health care
The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to sum...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Joana Oliveira [verfasserIn] Inês Neves [verfasserIn] Milene Fernandes [verfasserIn] Osvaldo Santos [verfasserIn] Vasco Maria [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Spanisch ; Portugiesisch |
| Erschienen: |
2019 |
|---|
| Übergeordnetes Werk: |
In: Revista Portuguesa de Medicina Geral e Familiar - Associação Portuguesa de Medicina Geral e Familiar, 2024, 35(2019), 4 |
|---|---|
| Übergeordnetes Werk: |
volume:35 ; year:2019 ; number:4 |
| Links: |
|---|
| DOI / URN: |
10.32385/rpmgf.v35i4.12239 |
|---|
| Katalog-ID: |
DOAJ100418007 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ100418007 | ||
| 003 | DE-627 | ||
| 005 | 20240414094611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.32385/rpmgf.v35i4.12239 |2 doi | |
| 035 | |a (DE-627)DOAJ100418007 | ||
| 035 | |a (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa |a por | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Joana Oliveira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. | ||
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Inês Neves |e verfasserin |4 aut | |
| 700 | 0 | |a Milene Fernandes |e verfasserin |4 aut | |
| 700 | 0 | |a Osvaldo Santos |e verfasserin |4 aut | |
| 700 | 0 | |a Vasco Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista Portuguesa de Medicina Geral e Familiar |d Associação Portuguesa de Medicina Geral e Familiar, 2024 |g 35(2019), 4 |w (DE-627)369556526 |w (DE-600)2119526-2 |x 21825181 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2019 |g number:4 |
| 856 | 4 | 0 | |u https://doi.org/10.32385/rpmgf.v35i4.12239 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 |z kostenfrei |
| 856 | 4 | 0 | |u https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2182-5181 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2019 |e 4 | ||
| author_variant |
j o jo i n in m f mf o s os v m vm |
|---|---|
| matchkey_str |
article:21825181:2019----::rsrbnadaiiaigihrwlrmezdaeie |
| hierarchy_sort_str |
2019 |
| callnumber-subject-code |
R |
| publishDate |
2019 |
| allfields |
10.32385/rpmgf.v35i4.12239 doi (DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 DE-627 ger DE-627 rakwb eng spa por R5-920 Joana Oliveira verfasserin aut Prescribing and facilitating withdrawal from benzodiazepines in primary health care 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. Medicine (General) Inês Neves verfasserin aut Milene Fernandes verfasserin aut Osvaldo Santos verfasserin aut Vasco Maria verfasserin aut In Revista Portuguesa de Medicina Geral e Familiar Associação Portuguesa de Medicina Geral e Familiar, 2024 35(2019), 4 (DE-627)369556526 (DE-600)2119526-2 21825181 nnns volume:35 year:2019 number:4 https://doi.org/10.32385/rpmgf.v35i4.12239 kostenfrei https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 kostenfrei https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 kostenfrei https://doaj.org/toc/2182-5181 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 35 2019 4 |
| spelling |
10.32385/rpmgf.v35i4.12239 doi (DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 DE-627 ger DE-627 rakwb eng spa por R5-920 Joana Oliveira verfasserin aut Prescribing and facilitating withdrawal from benzodiazepines in primary health care 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. Medicine (General) Inês Neves verfasserin aut Milene Fernandes verfasserin aut Osvaldo Santos verfasserin aut Vasco Maria verfasserin aut In Revista Portuguesa de Medicina Geral e Familiar Associação Portuguesa de Medicina Geral e Familiar, 2024 35(2019), 4 (DE-627)369556526 (DE-600)2119526-2 21825181 nnns volume:35 year:2019 number:4 https://doi.org/10.32385/rpmgf.v35i4.12239 kostenfrei https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 kostenfrei https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 kostenfrei https://doaj.org/toc/2182-5181 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 35 2019 4 |
| allfields_unstemmed |
10.32385/rpmgf.v35i4.12239 doi (DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 DE-627 ger DE-627 rakwb eng spa por R5-920 Joana Oliveira verfasserin aut Prescribing and facilitating withdrawal from benzodiazepines in primary health care 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. Medicine (General) Inês Neves verfasserin aut Milene Fernandes verfasserin aut Osvaldo Santos verfasserin aut Vasco Maria verfasserin aut In Revista Portuguesa de Medicina Geral e Familiar Associação Portuguesa de Medicina Geral e Familiar, 2024 35(2019), 4 (DE-627)369556526 (DE-600)2119526-2 21825181 nnns volume:35 year:2019 number:4 https://doi.org/10.32385/rpmgf.v35i4.12239 kostenfrei https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 kostenfrei https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 kostenfrei https://doaj.org/toc/2182-5181 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 35 2019 4 |
| allfieldsGer |
10.32385/rpmgf.v35i4.12239 doi (DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 DE-627 ger DE-627 rakwb eng spa por R5-920 Joana Oliveira verfasserin aut Prescribing and facilitating withdrawal from benzodiazepines in primary health care 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. Medicine (General) Inês Neves verfasserin aut Milene Fernandes verfasserin aut Osvaldo Santos verfasserin aut Vasco Maria verfasserin aut In Revista Portuguesa de Medicina Geral e Familiar Associação Portuguesa de Medicina Geral e Familiar, 2024 35(2019), 4 (DE-627)369556526 (DE-600)2119526-2 21825181 nnns volume:35 year:2019 number:4 https://doi.org/10.32385/rpmgf.v35i4.12239 kostenfrei https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 kostenfrei https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 kostenfrei https://doaj.org/toc/2182-5181 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 35 2019 4 |
| allfieldsSound |
10.32385/rpmgf.v35i4.12239 doi (DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 DE-627 ger DE-627 rakwb eng spa por R5-920 Joana Oliveira verfasserin aut Prescribing and facilitating withdrawal from benzodiazepines in primary health care 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. Medicine (General) Inês Neves verfasserin aut Milene Fernandes verfasserin aut Osvaldo Santos verfasserin aut Vasco Maria verfasserin aut In Revista Portuguesa de Medicina Geral e Familiar Associação Portuguesa de Medicina Geral e Familiar, 2024 35(2019), 4 (DE-627)369556526 (DE-600)2119526-2 21825181 nnns volume:35 year:2019 number:4 https://doi.org/10.32385/rpmgf.v35i4.12239 kostenfrei https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 kostenfrei https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 kostenfrei https://doaj.org/toc/2182-5181 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 35 2019 4 |
| language |
English Spanish Portuguese |
| source |
In Revista Portuguesa de Medicina Geral e Familiar 35(2019), 4 volume:35 year:2019 number:4 |
| sourceStr |
In Revista Portuguesa de Medicina Geral e Familiar 35(2019), 4 volume:35 year:2019 number:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Medicine (General) |
| isfreeaccess_bool |
true |
| container_title |
Revista Portuguesa de Medicina Geral e Familiar |
| authorswithroles_txt_mv |
Joana Oliveira @@aut@@ Inês Neves @@aut@@ Milene Fernandes @@aut@@ Osvaldo Santos @@aut@@ Vasco Maria @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
369556526 |
| id |
DOAJ100418007 |
| language_de |
englisch spanisch portugiesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100418007</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414094611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.32385/rpmgf.v35i4.12239</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100418007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Joana Oliveira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prescribing and facilitating withdrawal from benzodiazepines in primary health care</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. </subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Inês Neves</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milene Fernandes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osvaldo Santos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vasco Maria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Portuguesa de Medicina Geral e Familiar</subfield><subfield code="d">Associação Portuguesa de Medicina Geral e Familiar, 2024</subfield><subfield code="g">35(2019), 4</subfield><subfield code="w">(DE-627)369556526</subfield><subfield code="w">(DE-600)2119526-2</subfield><subfield code="x">21825181</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.32385/rpmgf.v35i4.12239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2182-5181</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Joana Oliveira |
| spellingShingle |
Joana Oliveira misc R5-920 misc Medicine (General) Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| authorStr |
Joana Oliveira |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)369556526 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R5-920 |
| illustrated |
Not Illustrated |
| issn |
21825181 |
| topic_title |
R5-920 Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| topic |
misc R5-920 misc Medicine (General) |
| topic_unstemmed |
misc R5-920 misc Medicine (General) |
| topic_browse |
misc R5-920 misc Medicine (General) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Revista Portuguesa de Medicina Geral e Familiar |
| hierarchy_parent_id |
369556526 |
| hierarchy_top_title |
Revista Portuguesa de Medicina Geral e Familiar |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)369556526 (DE-600)2119526-2 |
| title |
Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| ctrlnum |
(DE-627)DOAJ100418007 (DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8 |
| title_full |
Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| author_sort |
Joana Oliveira |
| journal |
Revista Portuguesa de Medicina Geral e Familiar |
| journalStr |
Revista Portuguesa de Medicina Geral e Familiar |
| callnumber-first-code |
R |
| lang_code |
eng spa por |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| author_browse |
Joana Oliveira Inês Neves Milene Fernandes Osvaldo Santos Vasco Maria |
| container_volume |
35 |
| class |
R5-920 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Joana Oliveira |
| doi_str_mv |
10.32385/rpmgf.v35i4.12239 |
| author2-role |
verfasserin |
| title_sort |
prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| callnumber |
R5-920 |
| title_auth |
Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| abstract |
The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. |
| abstractGer |
The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. |
| abstract_unstemmed |
The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
Prescribing and facilitating withdrawal from benzodiazepines in primary health care |
| url |
https://doi.org/10.32385/rpmgf.v35i4.12239 https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8 https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239 https://doaj.org/toc/2182-5181 |
| remote_bool |
true |
| author2 |
Inês Neves Milene Fernandes Osvaldo Santos Vasco Maria |
| author2Str |
Inês Neves Milene Fernandes Osvaldo Santos Vasco Maria |
| ppnlink |
369556526 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.32385/rpmgf.v35i4.12239 |
| callnumber-a |
R5-920 |
| up_date |
2024-07-03T14:32:38.531Z |
| _version_ |
1803568712034287616 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100418007</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414094611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.32385/rpmgf.v35i4.12239</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100418007</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ877762c5de7c4c7fb8563e304042ccd8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Joana Oliveira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prescribing and facilitating withdrawal from benzodiazepines in primary health care</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The chronic use of benzodiazepine anxiolytics and hypnotics is a controversial issue and it is envisaged by most family physicians as a health problem. Although benzodiazepines act rapidly and are well tolerated, its prevalent use is raising clinical concerns. A narrative review was conducted to summarize benzodiazepine indications, adverse effects and risks associated with overuse. Available strategies to discontinue these drugs at primary care setting are also explored. Benzodiazepines main indications are anxiety and insomnia, when the disorder is severe, disabling or subjecting the individual to extreme distress. However, treatment should be as short as possible, not exceeding eight to twelve weeks for anxiety or four weeks for insomnia. The evidence shows that systematic approaches with brief interventions and recommendation for gradual dose reduction of benzodiazepines seem to have good results among benzodiazepines users. This review is the first step of the development, implementation and effectiveness evaluation of a novel benzodiazepine withdrawal program, to be conducted by family doctors. </subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Inês Neves</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Milene Fernandes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osvaldo Santos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vasco Maria</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Portuguesa de Medicina Geral e Familiar</subfield><subfield code="d">Associação Portuguesa de Medicina Geral e Familiar, 2024</subfield><subfield code="g">35(2019), 4</subfield><subfield code="w">(DE-627)369556526</subfield><subfield code="w">(DE-600)2119526-2</subfield><subfield code="x">21825181</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.32385/rpmgf.v35i4.12239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/877762c5de7c4c7fb8563e304042ccd8</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12239</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2182-5181</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2019</subfield><subfield code="e">4</subfield></datafield></record></collection>
|
| score |
7.4012985 |